IRCT20200407046981N43 IRCT 2022-10-11 Kimia pharmaceutical Co Study of absorption and elimination rate of Ibrutinib 140 -mg Capsules in comparison with Ibrutinib brand capsules (Imbruvica®) Comparative bioequivalence study of the Ibrutinib 140 -mg Capsules manufactured by Noavaran Daroui Kimia Company with Ibrutinib brand capsules (Imbruvica®) by Janssen company 2022-12-06 anticipated 24 Complete https://irct.ir/trial/66107 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: To randomly assign people in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope after entering the study, and numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of the both groups will change for the second period. Bioequivalence bioequivalence study. Intervention 1: Intervention group 1: In this group, volunteers are given a single oral dose of Ibrotinib 140-mg Capsules produced by Noavaran Daroui Kimia Co. (Domestic). In each period, 12 of 24 subjects will be given single oral dose of this product. After the washout period, the volunteers are placed in the Intervention group 2. Intervention 2: Intervention group 2: In this group, volunteers are given a single oral dose of Ibrutinib 140 -mg Capsules (Ibrance®), produced by Pfizer Company (Brand). In each period, 12 of 24 subjects will be given single oral dose of this product. After the washout period, the volunteers are placed in the Intervention group 1. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information